Section Arrow
GNPX.NASDAQ
- Genprex Inc.
Quotes are at least 15-min delayed:2026/04/23 04:34 EDT
Pre Market
Last
 1.02
0 (0.00%)
Bid
1.02
Ask
1.04
High 1.04 
Low 1.01 
Volume 4.00K 
Regular Hours (Closed)
Last
 1.02
-0.07 (-6.42%)
Day High 
1.115 
Prev. Close
1.09 
1-M High
1.97 
Volume 
1.71M 
Bid
1.02
Ask
1.04
Day Low
1.01 
Open
1.115 
1-M Low
1.04 
Market Cap 
9.86M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.23 
20-SMA 1.47 
50-SMA 1.79 
52-W High 55 
52-W Low 1.04 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-17.40/-1.15
Enterprise Value
9.86M
Balance Sheet
Book Value Per Share
0.88
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.2224+0.0256+13.01%-- 
Pre Market 0.207 -0.0154 -6.92%
TOVXTheriva Biologics Inc0.3731+0.0344+10.16%0.09PE
Pre Market 0.3447 -0.0284 -7.61%
IOVAIovance Biotherapeutics3.53-0.17-4.59%-- 
Pre Market 3.5244 -0.0056 -0.16%
REPLReplimune Group2.27+0.41+22.04%-- 
Pre Market 2.28 +0.01 +0.44%
GERNGeron Corp1.55+0.05+3.33%-- 
Pre Market 1.56 +0.01 +0.65%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for largepatient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.